« Previous
Next »
Titles
- FDA repeatedly adapted emergency use authorization policies to address the need for COVID-19 testing1
- FDA’s approach to overseeing online tobacco retailers needs improvement1
- FDA’s work with the tri-agency task force for emergency diagnostics helped labs implement COVID-19 tests1
- Facet screw systems: performance criteria for safety and performance based pathway : guidance for industry and Food and Drug Administration staff1
- Failure to respond to an ANDA complete response letter within the regulatory timeframe1
- Failure to respond to an ANDA complete response letter within the regulatory timeframe: guidance for industry1
- Feasibility and early feasibility clinical studies for certain medical devices intended to therapeutically improve glycemic control in patients with Type 2 Diabetes Mellitus: guidance for industry and Food and Drug Administration staff1
- Federal Employees Health Benefits Program: Additional monitoring mechanisms and fraud risk assessment needed to better ensure member eligibility : report to congressional requesters1
- Federal economic stimulus projected to cut poverty in 2021, though poverty may rise as benefits expire1
- Federal efforts to address racial and ethnic disparities in Alzheimer’s disease and related dementias1
- Federal prisons: monitoring efforts to implement COVID-19 recommendations and examining first step act implementation : testimony before the Subcommittee on Crime, Terrorism, and Homeland Security, Committee on the Judiciary, House of Representatives1
- Flexibilities in controlled substances prescribing and dispensing during the COVID-19 pandemic1
- For Medicaid-enrolled children diagnosed with lead toxicity in five states, documentation reviewed for diagnoses and treatment services raises concerns1
- Formal meetings between FDA and ANDA applicants of complex products under GDUFA: guidance for industry1